三生制药SSGJ707 II期数据积极,创新药进入收获期

东吴证券
10 Mar

投资要点基本面扎实+创新药收获期赋予较大弹性。核心产品特比澳、促红素及蔓迪等贡献80多亿收入、20多亿利润,对应7倍PE,估计每年拥有近5-10%增长,近60亿现金资产全面支持创新药研发,年研发投入近10亿处于行业前列;多年创新药不仅孵化 三生国健 优质自免创新药平台,更培育出或合作开发SSGJ707、自免系列产品及口服紫杉醇等,尤其SSGJ707在J。P。M展示积极II数据,有BEST-IN-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10